EP4289427A1 — Dihydro[1,8]naphthyridin-7-one and pyrido[3,2-b][1,4]oxazin-3-one for use in treating cancer, and metastases in particular.
Assigned to Anagenesis Biotechnologies · Expires 2023-12-13 · 2y expired
What this patent protects
The invention provides compounds for treating, ameliorating, delaying, curing and/or preventing cancer. In particular, the invention relates to compounds of general formula (I) or a pharmaceutically acceptable salt thereof, and their use for treating cancer and/or for reducing or…
USPTO Abstract
The invention provides compounds for treating, ameliorating, delaying, curing and/or preventing cancer. In particular, the invention relates to compounds of general formula (I) or a pharmaceutically acceptable salt thereof, and their use for treating cancer and/or for reducing or preventing the appearance of metastases in a patient afflicted with a cancer. The invention also relates to new compounds of general formula (II) or a pharmaceutical acceptable salt thereof, and their use as a drug, in particular for treating cancer and/or for reducing or preventing the appearance of metastases in a patient afflicted with a cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.